- Danaher (NYSE: DHR) reported strong Q3 2026 earnings per share of $2.11, surpassing estimates, despite a slight revenue miss.
- The company highlighted improving customer demand and faster core revenue growth, excluding respiratory revenue, exceeding internal expectations.
- Key financial metrics include a trailing price-to-earnings ratio of 36.6, a price-to-sales ratio of 6.15, a debt-to-equity ratio of 0.49, and a current ratio of 1.63.
Danaher Corporation (NYSE: DHR), a life sciences and diagnostics company, reports third-quarter 2026 results before the market opens on October 21, 2026. Its businesses provide tools and tests used by researchers and health care providers. Thermo Fisher Scientific Inc. (NYSE: TMO) and Abbott Laboratories (NYSE: ABT) compete with parts of its business.
Danaher reports earnings per share of $2.11, above the $1.92 estimate. Revenue is $6.55 billion, just below the $6.56 billion estimate. Earnings per share show how much profit a company makes for each share.
The company says revenue, earnings and cash flow exceed its expectations, as highlighted by PR Newswire. That assessment differs from the supplied revenue estimate, which Danaher misses by $0.01 billion. Danaher also reports improving customer demand and faster core revenue growth when respiratory revenue is excluded.
CEO Julie Sawyer Montgomery credits stronger demand and the Danaher Business System, the company’s approach to improving operations, for double-digit growth in adjusted earnings per share. Adjusted earnings leave out certain items to help show ongoing performance. The company says its results and comparisons cover continuing operations and are year over year unless noted otherwise.
Danaher has a trailing price-to-earnings ratio of 36.6, meaning its share price is 36.6 times earnings from the past 12 months. Its price-to-sales ratio is 6.15, debt-to-equity ratio is 0.49, and current ratio is 1.63. The current ratio compares short-term assets with short-term debts.
